Enhancement of long-lasting immunoprotective effect against Androctonus australis hector envenomation using safe antigens: Comparative role of MF59 and Alum adjuvants

Nouri, Abdelmounaim; Laraba-Djebari, Fatima

doi:10.1016/j.vaccine.2015.09.045

Cited by 16 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We evaluated the immunogenicity and protective capacity of pEGFP-toxofilin DNA vaccine either alone, with the single adjuvants alum or MPLA, or combined alum-MPLA adjuvants. Incorporation of alone or mixed adjuvants significantly boosted the production of IgG titers following vaccination with the pEGFP-toxofilin DNA vaccine, inducing differential skewing of protective immunity compared with the non-adjuvanted toxofilin antigen, and to each adjuvant, as alum and MPLA induce different biases in the immune response [17, 18]. The alum-toxofilin group increased IgG1 levels compared with non-adjuvanted toxofilin, skewing the immune response towards a Th2 response associated with strong production of the IL-4, IL-10, and the IgG1 antibody subtype.…”

Section: Discussionmentioning

confidence: 99%

“…With the aim of developing a transmission-blocking T.gondii vaccine, the application of compound adjuvant has leaded the vaccine development to a new era, resulting in a stronger immune response through a synergistic effect. This strategy incorporating a combination of adjuvants (monophosphoryl lipid A (MPLA) and alum) is proven to be effective [17, 18]. MPLA as an adjuvant system have additive effects, especially intracellular processing of Th1 antigens by the major histocompatibility complex.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii

Song

Zhou

et al. 2017

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundA widely prevalent disease, toxoplasmosis poses serious health threats to both humans and animals; therefore, development of an ideal DNA vaccine against Toxoplasma gondii is needed eagerly. The purpose of the present study is to assess the protective efficacy of a DNA vaccine encoding the T. gondii toxofilin gene (pEGFP-toxofilin). In addition, toxofilin DNA vaccine combined with the individual adjuvants, alum or monophosphoryl lipid A (MPLA), or a mixture of alum-MPLA adjuvant were screened for their ability to enhance antibody responses.MethodsUsing bioinformatics, we analyzed the gene and amino acid sequences of the toxofilin protein, recognizing and identifying several potential linear B and T helper (Th)-1 cell epitopes. BALB/c mice were immunized three times with either toxofilin DNA vaccine alone or in combination with the adjuvants such as alum, MPLA or an alum-MPLA mixture. The systemic immune response was evaluated by cytokine, the percentage of CD4 (+) and CD8 (+) T cells and specific antibody measurement. Two weeks after the last immunization, protective efficacy was evaluated by challenging intraperitoneally with 1 × 104 tachyzoites of T. gondii or intragastrically with 20 cysts of T. gondii PRU strain.ResultsAll experimentally immunized mice developed strong humoral and cellular immune responses compared with the control groups. Moreover, by comparison with the non-adjuvant toxofilin DNA vaccine group, adding alum adjuvant to toxofilin DNA vaccine resulted in an increase in humoral response and a skewed Th2 response. However, the MPLA adjuvant with toxofilin DNA vaccine induced significantly enhanced humoral and Th1-biased immune responses. Importantly, the co-administration of alum-MPLA adjuvant in combination with the toxofilin DNA vaccine shifted the Th2 immune response to a Th1 response compared with the alum-toxofilin group, and elicited the strongest humoral and Th1 responses among all the groups. At the same time, a longer survival time and less cyst amounts against T. gondii infection were also observed in the alum-MPLA-toxofilin group in comparison with single or no adjuvant groups.Conclusions Toxoplasma gondii toxofilin is a promising vaccine candidate that warrants further development. Co-administration of the alum-MPLA adjuvant mixture with DNA vaccine could effectively enhance immunogenicity and strongly skew the cellular immune response towards a Th1 phenotype.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii

Song

Zhou

et al. 2017

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…It is worth noting that a prophylactic treatment could be used to prevent the induced pathophysiological effects and the lethality of scorpion envenomation [133,134,135]. The development of a vaccine-like product could enhance the immune responses to a specific antigen without deleterious side effects caused by adjuvants [136].…”

Section: Advanced Scorpion Envenomation Therapiesmentioning

confidence: 99%

Serotherapy against Voltage-Gated Sodium Channel-Targeting α-Toxins from Androctonus Scorpion Venom

Martin‐Eauclaire

Adi-Bessalem

Hammoudi-Triki

et al. 2019

Toxins

Self Cite

View full text Add to dashboard Cite

Because of their venom lethality towards mammals, scorpions of the Androctonus genus are considered a critical threat to human health in North Africa. Several decades of exploration have led to a comprehensive inventory of their venom components at chemical, pharmacological, and immunological levels. Typically, these venoms contain selective and high affinity ligands for the voltage-gated sodium (Nav) and potassium (Kv) channels that dictate cellular excitability. In the well-studied Androctonus australis and Androctonus mauretanicus venoms, almost all the lethality in mammals is due to the so-called α-toxins. These peptides commonly delay the fast inactivation process of Nav channels, which leads to increased sodium entry and a subsequent cell membrane depolarization. Markedly, their neutralization by specific antisera has been shown to completely inhibit the venom’s lethal activity, because they are not only the most abundant venom peptide but also the most fatal. However, the structural and antigenic polymorphisms in the α-toxin family pose challenges to the design of efficient serotherapies. In this review, we discuss past and present accomplishments to improve serotherapy against Androctonus scorpion stings.

show abstract

“…MF59 can mobilize immune cells to the injection site, and the main cell type that MF59 acting mainly on monocytes [ 9 ], which can be recruited to the site of adjuvant action, absorb antigens, and participate in the adjuvant-induced differentiation of the dendritic cell phenotype [ 41 ]. MF59 recruits APC for antigen presentation and transport to draining lymph nodes [ 42 ] and promotes antigen retention in lymph nodes and follicular dendritic cells [ 43 ].…”

Section: Classification and Mechanism Of Emulsion-based Adjuvantsmentioning

confidence: 99%

Research progress on emulsion vaccine adjuvants

Huang,

Gong,

Sun

et al. 2024

Heliyon

View full text Add to dashboard Cite

Enhancement of long-lasting immunoprotective effect against Androctonus australis hector envenomation using safe antigens: Comparative role of MF59 and Alum adjuvants

Cited by 16 publications

References 29 publications

Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii

Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii

Serotherapy against Voltage-Gated Sodium Channel-Targeting α-Toxins from Androctonus Scorpion Venom

Research progress on emulsion vaccine adjuvants

Contact Info

Product

Resources

About